Mr Vickery has over 25 years’ experience as a finance professional, with a particular focus on life sciences and innovation-based businesses. As Chief Financial Officer (CFO) of Viralytics, he was a key member of the team that accomplished the acquisition by Merck in June 2018 -- the largest ever transaction in the Australian biotech sector. While at Viralytics, Mr. Vickery managed several other major capital transactions and re-engineered key corporate functions, including IT, HR and insurance.
He has previously held senior roles with several biotech and innovation-based businesses, including as CFO and Company Secretary of ASX listed BioSignal Ltd. Early in his career he served in the Chartered Accounting profession before transitioning to a corporate role at Swire Group acting across a range of treasury, taxation and company secretarial functions. Mr. Vickery is an Associate of the Institute of Chartered Accountants and the Governance Institute of Australia.